Skip to content

蓝瑟斯

US · LNTH #1847 按市值排名 上市于 2015
99.70 -0.29 -0.29%
实时 - 追踪5344个代码 - 心跳于139秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 4.97 低于历史水平 第29百分位
5年平均 6.53 · 在Drug Manufacturers - Specialty & Generic中排名第53/70
市盈率 23.90 处于历史正常水平 第61百分位
5年平均 10.16 · 前瞻 18.43 · 在Drug Manufacturers - Specialty & Generic中排名第17/25
市销率 4.19 处于历史正常水平 第43百分位
5年平均 4.76 · 前瞻 4.26 · 在Drug Manufacturers - Specialty & Generic中排名第55/80

同业对比 Drug Manufacturers - Specialty & Generic

公司 市值 市盈率(TTM) 市净率 股息率
蓝瑟斯 (LNTH) 6.51B 23.85 4.96 0.00%
Takeda Pharmaceutical (TAK) 62.84B -59.43 1.31 3.04%
Teva Pharmaceutical Industries (TEVA) 48.40B 69.17 6.24 0.00%
Haleon (HLN) 44.55B 21.06 2.05 1.88%
Zoetis (ZTS) 32.80B 12.95 10.42 2.60%
United Therapeutics (UTHR) 22.87B 19.10 3.57 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★☆☆☆ 合理价值84.51 经济护城河Narrow 不确定性High

当前股价高于晨星合理价值估算15.2%。

合理价值

Lantheus Holdings Inc receives a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 19% premium over our quantitative fair value estimate of $84.51 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 20.1% falls in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

On a different note, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 6.0%, for example, sits in the top 40% globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:30 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

蓝瑟斯 讨论区 0 条评论

发表评论